EGFR and non-small cell lung carcinoma: EGFR was discovered in 1977, and EGFR mutations were found to predict sensitivity to gefitinib among NSCLC patients at the beginning of the twenty-first century, which showed encouraging efficacy in EGFR-mutated NSCLC in clinical trials, indicating that the treatment of NSCLC has entered the era of targeted therapy [31, 32].